1. Background {#sec1}
=============

Primary isolated amyloidosis involving the respiratory tract is a rare disease. It mostly affects the trachea and central bronchi [@bib1; @bib2], but amyloid deposits in other sections of the airways alone or in combination with tracheobronchial amyloidosis (TBA) have been reported [@bib3; @bib4; @bib5]. TBA is typically not associated with systemic amyloidosis or pulmonary parenchymal deposits such as in Sjogren\'s syndrome. It represents a localized variant of amyloidosis and is characterized by multiple amyloid deposits within the airway walls [@bib6].

The diagnosis of TBA is often delayed, as affected patients have signs and symptoms not differ from common airway diseases. Pulmonary function tests may or may not reveal an obstructive pattern. Chest x-rays are frequently unremarkable or a tracheal mass is overlooked. On computer tomography, diffuse TBA leads to concentric smooth or nodular thickening of the submucosal tracheal wall. The diagnosis of TBA is made by means of bronchoscopy and biopsy of airway mucosa [@bib1; @bib7; @bib8].

Management of this disease is directed at maintaining airway patency, but no general consensus exists with regard to optimal treatment, as debridement is often associated with severe and prolonged bleeding.

We report the case of a 50 year old woman with concurrent amyloidosis of the tracheobronchial tree and the upper airways. Our case illustrates the necessity for a multidisciplinary approach, including respiratory medicine and otorhinolaryngology, radiology, pathology and radiotherapy to achieve an accurate and timely diagnosis of this uncommon disorder and to offer currently optimal therapy.

2. Case presentation {#sec2}
====================

A 50 year old woman was admitted to the hospital for bronchoscopic evaluation. She was an active smoker with a cigarette smoking history of 30 pack years and had suffered from repeated bronchitis, shortage of breath and hoarseness as well as repeated episodes of hemoptysis. She also complained of nasal congestion and recurrent sinusitis. A pulmonary infiltrate in the right upper lobe had not resolved after antibiotic treatment.

On clinical examination, stridor was audible in the central airways. The physical examination of other organ systems was not remarkable. Laboratory investigations included normal blood count, normal erythrocyte sedimentation rate and normal biochemistry. A computer tomography scan revealed an atelectasis of the right upper lobe and diffuse nodular thickening of the submucosal tracheal and bronchial walls ([Fig. 1](#fig1){ref-type="fig"}). The cartilage showed calcifications. There were no other parenchymal abnormalities. Arterial blood gases, while breathing room air, were normal. Pulmonary function tests revealed normal FVC, FEV1, FEV1/FVC; but decreased PEF and an expiratory plateau in the flow volume loop, suggestive of intrathoracic stenosis ([Fig. 2](#fig2){ref-type="fig"}).

Flexible bronchoscopy was performed and a completely irregular surface of the tracheal and bronchial mucosa with prominent white and reddish plaques, extending the lower half of the trachea and main bronchi with reduced airway diameters and diffuse bleeding was found ([Fig. 3](#fig3){ref-type="fig"}). Biopsies showed amorphous deposits, identified as amyloid by apple-green birefringence in sections stained with congo red and seen under polarized light. Immunohistochemical staining demonstrated AL amyloid. Systemic amyloidosis was excluded by normal serum protein electrophoresis, normal urine analyses (no Bence Jones protein in the urin), normal rectal biopsy specimens, normal bone marrow aspiration/biopsy, normal echocardiography and abdominal ultrasound.

The patient underwent bronchoscopic debridement with forceps debulking for more extensive bioptic work-up and treatment of airway stenosis. The procedure was complicated by prolonged but self-limited bleeding. The case was discussed at the multidisciplinary respiratory oncology board and it was felt that external beam radiation therapy (EBRT) was an appropriate treatment option. Radiation therapy was explained in detail to the patient because of the scarcity of clinical data regarding its use for TBA. She received EBRT, 20 Gy in 10 fractions. Opposed anterio-posterior and posterior-anterior treatment fields were used to encompass the entire tracheobronchial tree. The treatment volume was determined using CT-guided simulation. Treatment was uneventful. Clinically her symptoms improved and the pulmonary function test stabilized during 12 month follow-up. Chest x-rays at 6 months and CT scans at 12 months after radiation therapy revealed that response to radiation was maintained, with no evidence of disease progression.

Meanwhile the symptoms of chronic sinusitis and nasal congestion worsened. She was transferred to the department of Otolaryngology/Head and Neck Surgery where a CT scan revealed a mass at the bottom of the left maxillary sinus and the nasopharynx. Surgical excision confirmed amyloid deposits submucosally at the roof of the nasopharynx. Functional endoscopic sinus surgery (FEES) was performed to ventilate the left maxillary sinus. To date no further treatment has been necessary.

3. Discussion {#sec3}
=============

Amyloidosis restricted to the respiratory tract is a rare manifestation of an otherwise rare disorder. Less than 250 cases of pulmonary amyloidosis have been reported, predominantly as anecdotal reports or small series [@bib1; @bib2]. Localized pulmonary amyloidosis can manifest as parenchymal nodules, diffuse alveolar septal disease, or mostly tracheobronchial disease. Isolated nasal amyloidosis is extremely uncommon, some 20 cases have been reported in the literature [@bib4; @bib5; @bib9; @bib10; @bib11; @bib12; @bib13]. Only a few cases with multifocal amyloidosis of the upper and lower airways have been described. By definition, localized amyloidosis affects only one organ system and inevitably occurs without systemic amyloidosis. It is not understood, why these disease processes are limited to the respiratory tract, but it has been proposed that light chains are deposited locally by plasma cells.

The condition tends to have a progressive course where up to 30% of patients with TBA may not survive beyond seven to twelve years after diagnosis [@bib6] due to narrowing airways. There is no established treatment for TBA. Review of the literature shows that information about TBA is limited to small case series or case reports. Generally, the treatment options, as gathered from published data, can be categorized into 4 not necessarily exclusive groups: [@bib1] systemic pharmacologic treatment, [@bib2] bronchoscopic recanalisation techniques [@bib3] the use of external beam radiation therapy and [@bib4] surgery in a few cases.

Pharmacologic treatment with colchicine has been tried, although the evidence for its use is based on non-controlled trials that have suggested that adjuvant treatment in primary systemic amyloidosis may have some benefit. Systemic intermittent chemotherapy using melphalan and prednisolone has been prescribed with limited success and there is no proof, that pharmacologic treatment following repeated laser resection is synergistic [@bib8; @bib14].

Bronchoscopic debulking with forceps or laser can be effective for a short time [@bib12; @bib15], but does not slow down the underlying disease process. Bronchoscopic recanalization techniques are limited by severe bleeding [@bib16] and the near inevitability of short term recurrence of the amyloid deposits.

Based on small series and few case reports, it appears that radiation therapy may change the progressive course of TBA [@bib17; @bib18; @bib19; @bib20; @bib21; @bib22; @bib23; @bib24]. EBRT is now recommended as a first -line therapy in patients with bulky or distal disease that is not amenable for bronchoscopic recanalization, especially if there is evidence of severe symptoms or functional decline. The successful use of radiation therapy for the treatment of TBA was first described by Kurrus et al. as a case report in 1998 [@bib24]. A patient with life-threatening airway obstruction secondary to TBA received 20 Gy in 10 fractions to the distal and right main bronchi and 6 months later to the lower lobe bronchi. In both areas treated the patient responded radiologically and symptomatically. The benefits of EBRT were maintained in anecdotal cases for more than 5 years [@bib18; @bib20]. The mechanisms underlying the therapeutic effects of EBRT are unknown. Generally, patients treated with EBRT achieve a rapid symptomatic response as well as an objective improvement of pulmonary function tests, CT scan findings and bronchoscopic appearance. EBRT was well tolerated. However, the long-term effects of radiation therapy are still unknown in these patients and only few patients received a second course.

4. Conclusions {#sec4}
==============

TBA remains a rare and clinically challenging condition. The treatment of this disease needs to be evaluated on a case by case basis and managed with an appropriate multidisciplinary team including the evaluation of the upper airways. EBRT is a promising and well tolerated treatment option. Close follow-up to detect late re-occurrence of the disorder or complications of EBRT is required.
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